Viewing
|Articles|May 31, 2012

Bevacizumab improves BCVA and central macular thickness in CSME patients

Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME